A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Sponsor

Image
Takeda Logo

Contact Info

Takeda Contact

1-877-825-3327

medinfoUS@takeda.com

Start Date: May 6, 2025 End Date: May 1, 2032

ClinicalTrials.gov Identifier: NCT06499285

Clinical Trial: A type of research study that tests how a drug, medical device, or treatment approach works in people. There are several types of clinical trials. Treatment trials test new treatment options. Diagnostic trials test new ways to diagnose a disease. Screening trials test the best way to detect a disease or health problem. Quality of life (supportive care) trials study ways to improve the comfort of people with chronic illness. Prevention trials look for better ways to prevent disease in people who have never had the disease. Trials are in four phases. Phase I tests a new drug or treatment in a small group to see if it is safe. Phase II expands the study to a larger group of people to find out if it works. Phase III expands the study to an even larger group of people to compare it to the standard treatment for the disease; and Phase IV takes place after the drug or treatment has been licensed and marketed to find out the long-term impact of the new treatment. If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the trial sponsor.

Purpose

The primary goal of this RENEW study is to find out how well elritercept works in lowering the need for red blood cell: The most numerous type of blood cell in healthy people. Red blood cells contain hemoglobin, a protein that picks up oxygen in the lungs and brings it to cells in all parts of the body. Also called erythrocyte, RBC. (RBC) transfusions.  Other aims are to learn how well elitercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs.  The study will also check on how safe elritercept is and how well it is tolerated.

Status
Recruiting
Bone Marrow Disease(s)
Myelodysplastic Syndromes (MDS)
Phase
Phase 3
Gender
Female
Male
Age Group
18 years and older
Accepts Healthy Volunteers
No
Inclusion Criteria
  • Over 18 years of age
  • Diagnosed with very low-, low-, or intermediate-risk MDS with transfusion-dependent anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count. Symptoms of anemia are fatigue and tiredness.
  • Refractory: Not responsive to treatment or cure. For example, refractory anemia is a low red blood cell count that doesn't respond to standard treatments. or intolerant to prior erythropoiesis-stimulating agents (ESA)
  • Does not have del(5q) MDS, secondary MDS: A type of MDS that is caused by a previous treatment foranother another disorder or disease. Treatments typically associated with secondary MDS include radiation therapy and chemotherapy used to treat cancer. Also called therapy-related MDS, T-MDS. , or AML
  • No prior use of TGF-β modulating therapy, hypomethylating agents (HMAs), isocitrate dehydrogenase inhibitor, lenalidomide: Lenalidomide is a capsule that is taken by mouth. It is approved for treating low-risk, transfusion-dependent myelodysplastic syndrome (MDS) patients with an abnormality of chromosome 5q. It is currently in clinical trials to test its efficacy with a broader range of MDS patients. For some MDS… , imetelstat: Who should not take RYTELO? Before taking RYTELO, tell your healthcare provider about all your medical conditions, including if you: are pregnant or plan to become pregnant. RYTELO may harm your unborn baby and may cause loss of pregnancy. Tell your healthcare provider right away if you… , or immunosuppressive therapy: Immunosuppressive drug therapy lowers your body's immune response. This prevents your immune system from attacking your bone marrow, allowing bone marrow stem cells to grow, which raises blood counts. For older patients with acquired aplastic anemia, immunosuppressive drug therapy is the… given for treatment of MDS 
  • Have not previously received luspatercept (Reblozyl®)
Exclusion Criteria
  • Del(5q) MDS or therapy-related (secondary) MDS.
  • Anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count. Symptoms of anemia are fatigue and tiredness. due to any other known cause (e.g., thalassemia, hemolytic anemia: Anemia due primarily to the excessive hemolysis or destruction of red blood cells , bleeding events, or deficiency of iron, B12, and/or folate: (FOE-late) A B-vitamin that is found in fresh or lightly cooked green vegetables. It helps the bone marrow make normal blood cells. Most people get enough folate in their diet. Doctors may have people with paroxysmal nocturnal hemaglobinuria (PNH) take a man-made form of folate called folic acid. ).
  • Receipt of RBC transfusion for any reason(s) other than underlying MDS within 16 weeks before randomization.

Find Out More:

Disclaimer:

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored content is highlighted only to give additional information about the trial. All trials are listed on https://clinicaltrials.gov/. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a clinical trial, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.